Mar. 16 at 1:18 AM
$LCTX What acquisition timing could look like.
Some Typical scenarios in biotech partnerships.
Stage and
Acquisition likelihood,
After strong Phase 2
common
During Phase 3
common
After approval
less common (much more expensive)
If OpRegen performs well, the highest probability window is often between Phase 2 data and Phase 3 enrollment.
Biotech acquisitions often occur at 5-10× prior trading price when pivotal assets are validated.
Again, that depends heavily on clinical success.
Recall- "This is one of the programs we're most excited about".
"They are seeing something special, we just need to be patient".
I'm of the belief that Culley and team are managing the 30M annual budget to create a meaningful and valuable company. I feel they are trying to seal that value as soon as possible.
If clinical progress continues, OpRegen could represent a strategic regenerative ophthalmology asset for Roche/Genentech, making full ownership a rational long-term scenario.
